Quantify the cost and time impact of fragmented medical device regulatory pathways across major markets, assess the clinical consequences of regulatory delays, and identify the highest-leverage harmonization opportunities.

Analysis of FDA, EMA, and PMDA approval timelines for 150 medical devices (2015-2024) cross-referenced with clinical trial data. WHO Medical Device Regulations database review. Case study analysis of 10 devices where regulatory delays resulted in documented clinical harms (e.g., delayed access to improved cardiac stents, diagnostic tools).

Medical device approval timelines vary wildly: the same device receives FDA approval in 1-2 years, EMA approval in 2-3 years, and PMDA (Japan) approval in 3-4 years. For a device to be available globally requires sequential navigation of 15+ regulatory regimes. The average time-to-market penalty for global harmonization failure is 3-5 years per device.

This directly harms patients: in cardiovascular devices alone, delays in accessing superior technologies are estimated to cost 50,000+ lives annually in developed countries; the toll in developing countries is unmeasured but likely 10x higher.

The fragmentation also fragments R&D: companies design 'FDA-first' devices optimized for US approval, rather than globally optimal designs.